Sarah Cannon | Strategic Alliance Partners

Sarah Cannon, the Cancer Institute of HCA Healthcare, offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, ~1,200 stem cell transplants performed annually throughout the Sarah Cannon Transplant and Cellular Therapy Network, hundreds of clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing world-class cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit sarahcannon.com.

Connect with us:

Latest from Sarah Cannon


CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma

April 25, 2022

The novel allogeneic CAR-engineered natural killer cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia and non-Hodgkin lymphoma.

KIN-2787 Looks to Fill Unmet Need in Class II/III BRAF-Altered Solid Tumors

February 22, 2022

Investigators hope to address the need for additional treatment options for patients with class II or class III BRAF-altered disease with KIN-2787, a next-generation, orally available, potent, and selective small molecule inhibitor.

Personalized Medicine Approaches Continue to Gain Steam in BRAF/NRAS+ Metastatic Melanoma

February 09, 2022

Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.

Immunotherapy Continues to Touch All Areas of Lung Cancer Treatment

January 09, 2022

David Spigel, MD, discussed the focus of each presentation, which centered on immunotherapy vs chemoimmunotherapy in the frontline metastatic setting, the surgical perspective of treatment in early-stage NSCLC, best practices for molecular testing, and EGFR- and KRAS-targeted therapies for patients with advanced disease.

Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC

October 25, 2021

Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.

Sarah Cannon Research Institute Experts Pinpoint Open Clinical Trials in Tennessee

October 11, 2021

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

SERDs, ADCs Broaden Research Avenues Throughout Breast Cancer

October 08, 2021

Selective estrogen receptor degraders and antibody-drug conjugates are not only broadening the armamentarium in breast cancer but are demonstrating increasing utility across subtypes and in underserved populations, such as those with HER2-low disease, explained Erika P. Hamilton, MD.